Integrated Advisors Network LLC Purchases 7,030 Shares of IQVIA Holdings Inc. (NYSE:IQV) (2024)

Integrated Advisors Network LLC boosted its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 141.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 12,002 shares of the medical research company's stock after acquiring an additional 7,030 shares during the period. Integrated Advisors Network LLC's holdings in IQVIA were worth $2,777,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in IQV. Norges Bank bought a new stake in IQVIA in the 4th quarter valued at about $383,705,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its holdings in shares of IQVIA by 339.6% in the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,067,195 shares of the medical research company's stock worth $478,308,000 after buying an additional 1,597,003 shares in the last quarter. Morningstar Investment Services LLC lifted its holdings in shares of IQVIA by 96.9% in the fourth quarter. Morningstar Investment Services LLC now owns 1,231,916 shares of the medical research company's stock worth $286,704,000 after buying an additional 606,333 shares in the last quarter. Capital Research Global Investors lifted its holdings in shares of IQVIA by 42.2% in the fourth quarter. Capital Research Global Investors now owns 1,995,269 shares of the medical research company's stock worth $461,675,000 after buying an additional 592,372 shares in the last quarter. Finally, Eagle Asset Management Inc. purchased a new stake in shares of IQVIA in the third quarter worth about $102,982,000. 89.62% of the stock is currently owned by institutional investors.

IQVIA Trading Down 0.6 %

NYSE:IQV traded down $1.21 during trading hours on Friday, hitting $212.75. The company had a trading volume of 845,033 shares, compared to its average volume of 1,199,631. The company has a market capitalization of $38.76 billion, a PE ratio of 29.06, a price-to-earnings-growth ratio of 1.95 and a beta of 1.53. The stock has a 50-day moving average price of $228.15 and a 200 day moving average price of $230.19. IQVIA Holdings Inc. has a 52 week low of $167.42 and a 52 week high of $261.73. The company has a debt-to-equity ratio of 2.02, a current ratio of 0.88 and a quick ratio of 0.88.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings data on Thursday, May 2nd. The medical research company reported $2.30 EPS for the quarter, beating the consensus estimate of $2.19 by $0.11. The business had revenue of $3.74 billion during the quarter, compared to analyst estimates of $3.69 billion. IQVIA had a return on equity of 29.17% and a net margin of 9.01%. On average, equities research analysts predict that IQVIA Holdings Inc. will post 10.11 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

IQV has been the topic of a number of recent analyst reports. The Goldman Sachs Group initiated coverage on shares of IQVIA in a report on Thursday, June 6th. They issued a "buy" rating and a $270.00 price target on the stock. Truist Financial lowered their target price on shares of IQVIA from $297.00 to $292.00 and set a "buy" rating on the stock in a research note on Friday, May 3rd. SVB Leerink initiated coverage on shares of IQVIA in a research note on Monday, February 26th. They issued an "outperform" rating and a $290.00 target price on the stock. Evercore ISI lowered their target price on shares of IQVIA from $275.00 to $250.00 and set an "outperform" rating on the stock in a research note on Friday, May 3rd. Finally, Robert W. Baird decreased their price target on shares of IQVIA from $254.00 to $245.00 and set a "neutral" rating on the stock in a research note on Friday, May 3rd. Three investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $258.40.

Read Our Latest Analysis on IQVIA

IQVIA Profile

(Free Report)

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Further Reading

• Five stocks we like better than IQVIA
• Upcoming IPO Stock Lockup Period, Explained
• MarketBeat Week in Review – 6/10 - 6/14
• Using the MarketBeat Dividend Tax Calculator
• Top 5 High-Performance Cryptocurrency ETFs to Watch
• Low PE Growth Stocks: Unlocking Investment Opportunities
• 3 Stocks That Plummeted After the Post-Fed Speech Crash

Should you invest $1,000 in IQVIA right now?

Before you consider IQVIA, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.

While IQVIA currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here